Search

file (14) (1)

Investor Overview

Investor Overview

HOMEInvestor Overview

Read More

2026.Feb.24

News

OBI Presents Next-Generation Bispecific Dual-Payload ADC Development at World ADC London 2026

2025.Dec.19

News

OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC

2025.Dec.18

News

OBI Investors’ Meeting Highlights Value Transformation Driven by ADC Innovation

Read More

2026.Feb.26

Announcement

Announcement for the expected date of the Board of Directors Meeting for 2025 financial reports is 2026/03/09

2026.Feb.04

Announcement

The Company received notice from SWOG regarding the analysis results of Phase II Stage 1 clinical trial of OBI-3424 in T-ALL and T-LBL

2025.Dec.31

Announcement

Announcement of completion of the Company’s capital change registration and adjustment to the share replacement plan

2024 Annual Report

Learn how we created value in 2024 and worked to pursue our purpose of enabling a healthier world.

Download PDF
Read More

Featured
Presentation

2025 Investors' Meeting - Driving Value Transformation Through ADC Innovation

Download PDF

Read More

2025 First Extraordinary General Shareholders’ Meeting

  • 2025.Oct.20 at 09:00 AM
  • Taipei Bioinnovation Park 1F Conference Room
Youtube

Governance

Read More

Corporate
Overview​

Board of
Directors​

Special ​
Committee​

Integrity​

Internal
Audit​

Governance
Document​

Investor Relations

Contact